Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. Mai 2020 11:00 ET | Quelle: CohBar, Inc.

CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine

MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
30. April 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020

MENLO PARK, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
14. April 2020 08:30 ET | Quelle: CohBar, Inc.

CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference

MENLO PARK, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
30. März 2020 08:45 ET | Quelle: CohBar, Inc.

CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity

MENLO PARK, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
12. März 2020 16:02 ET | Quelle: CohBar, Inc.

CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
12. März 2020 08:30 ET | Quelle: CohBar, Inc.

CohBar to Hold Investor Meetings at the ROTH Virtual Conference

MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
02. März 2020 16:30 ET | Quelle: CohBar, Inc.

CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020

MENLO PARK, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
28. Januar 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar to Present at the 2020 BIO CEO & Investor Conference

MENLO PARK, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
22. Januar 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar Appoints Jordyn Tarazi as Director of Investor Relations

MENLO PARK, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
08. Januar 2020 09:00 ET | Quelle: CohBar, Inc.

CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis

MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...

Vorherige Seite

Nächste Seite